MedTrace Logo

Liquid Biopsy in Hepatocellular Carcinoma

NCT04111029 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2023-05-03

No results posted yet for this study

Summary

Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required to assess cancer progression and characterize underlying genomic features. Use of 'liquid biopsy' by assessing circulating cell free DNA enables the clinician to offer targeted immunotherapy or signaling pathway inhibitors. It also offers a model to prove response to locoregional or immunotherapy therapy and predict tumor recurrence non-invasively.

Conditions

  • Hepatic Carcinoma Malignant Primary Non-Resectable

Interventions

DIAGNOSTIC_TEST

Cell Free DNA

Pre and post procedure plasma cell free DNA will be assessed for response to locoregional therapy

Sponsors & Collaborators

  • Post Graduate Institute of Medical Education and Research, Chandigarh

    lead OTHER

Principal Investigators

  • Radhika Srinivasan, MD PhD · Post Graduate Institute of Medical Education and Research, Chandigarh

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-16
Primary Completion
2023-12-16
Completion
2024-03-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04111029 on ClinicalTrials.gov